Authors
Yan Zhang, Anna Kozlowska, Jacqueline Fritz, Yingying Zhao, Claudia Palomino La Torre, Stacey Cranert, Steven Wang, Rebecca Codde, Elvira Argus, Samad Ibitokou, Vanitra Richardson, Sumiti Jain, Maximilian Richter, Deepak Patil, Yening Tan, Min Tong, Yao Lu, Majid Ghoddusi, Eric Ostertag, Julia Coronella, Devon Shedlock
Publication date
2021/11/1
Journal
Journal for ImmunoTherapy of Cancer
Volume
9
Issue
Suppl 2
Pages
A132-A132
Publisher
BMJ Publishing Group LTD
Description
RESULTS
Figure 2. P-MUC1C-ALLO1 cells demonstrate robust efficacy in TNBC MDA-MB-468 xenograft models. Caliper measurements of NSG mice bearing established subcutaneous MDA-MB-468 TNBC tumors. Mice were treated intraperitoneally with the indicated doses of MUC1C CAR-T cells at day 0. Tumor volume assessments by caliper measurement across study timepoints are shown (A). P-MUC1C-ALLO1 CAR-T proliferates in peripheral Blood. Total CAR-T cells in blood as measured at study time points by TruCount staining for human CD45+ cells per µl for all animals (B). Phenotype of CD8+ T cells in blood as measured by FACS staining for all animals as displayed as group averages at 106 CAR-T dose with error bars as SEM (C).
Total citations
Scholar articles
Y Zhang, A Kozlowska, J Fritz, YY Zhao, CP La Torre… - J Immunother Cancer, 2021